Trial shows success in treating drug-resistant TB
A 26-week treatment of 109 XDR-TB and MDR-TB patients with three oral drugs — bedaquiline, pretomanid, and linezolid — showed 90% success rate. There were seven deaths and two had…
Category: MDR-TB
Pretomanid: XDR-TB may soon become easily treatable
Though the total number of people with XDR-TB and treatment intolerant or non-responsive MDR-TB who will require the new anti-TB drug Pretomanid may not be high, these are people who…
Explainer: What makes the new drug-resistant TB medicine Pretomanid promising
When used in combination with bedaquiline and linezolid, the newly approved pretomanid drug for MDR-TB and XDR-TB had an overall treatment success rate of about 90%. Besides better effectiveness, the…
Majority of MDR-TB cases in India due to direct transmission: Lancet
While India has set a highly ambitious target of “eliminating TB by 2025”, modelling studies published today say incidence and mortality will reduce by just 57% and 72% respectively by…
Small DNA-based inhibitor blocks entry of TB bacteria into host cells
A team of researchers from three institutions in India has used aptamer-based inhibitor that binds to the HupB protein found on TB bacteria cell surface to significantly inhibit the entry…
MDR-TB treatment gets a boost with the inclusion of bedaquiline in the fully-oral regimen
In a “rapid communication”, WHO has informed all member States to take “immediate steps” to ensure that all injectables are replaced with a fully-oral regimen that includes bedaquiline to treat…
WHO revises advice on use of delamanid drug in MDR-TB patients
In a Phase III trial, delamanid drug was found to be safe but the cure rate and mortality rate were not different between the group that received the delamanid drug…
A glimmer of hope as India’s war on TB gets more funding
There is a glimmer of hope with India registering a slight drop in the number of new tuberculosis cases and TB deaths in 2016 compared with 2015. From an estimated…
